• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
Mad Hedge Fund Trader

The Netflix Earnings Shocker

Tech Letter

Netflix is saying no to over $2 billion in extra digital ad revenue – that is the critical takeaway from Netflix’s earnings call that fell in line with exactly what I thought would transpire.

As Netflix’s domestic subscriptions continue to soften, this is the first of many earnings calls where management will be put to the sword on why they still haven’t swiveled to digital ads.

As you guessed right, Founder and CEO Reed Hastings pulled out all the usual excuses explaining why Netflix is leaving a massive chunk of revenue on the table.

Some of his evasive rhetoric came in the form of explaining there’s no “easy money” in an online advertising business that has to compete with the likes of Google, Amazon, and Facebook.

He continued to spruce up his excuses by saying, “Google and Facebook and Amazon are tremendously powerful at online advertising because they’re integrating so much data from so many sources. There’s a business cost to that, but that makes the advertising more targeted and effective. So I think those three are going to get most of the online advertising business.”

Even most peons would understand that Netflix’s network effect is so robust that they could turn on the digital ad revenue spigots with a flick of a wrist. 

It doesn’t matter that there are also three other tech firms in the digital ad sphere.

Netflix certainly has the infrastructure in place and manpower laid out to harness the power lines of the digital ad game.

Hastings weirdly lamented that revenue would need to be “ripped away” from the existing providers, he continued. And stealing online advertising business from Amazon, Google and Facebook is “quite challenging.”

I don’t believe that is entirely accurate.

Dipping into that digital ad revenue would be quite challenging if you are a 2-man start-up, but the power centrifuge that has become to be known as Netflix is stark crazy for taking the high road on data privacy when the US government still allows tech companies to profit off of digital ads.

The musical chairs might stop in less than 3 years, but not now.

It’s hard to understand why Netflix isn’t approaching this as a short-term smash and grab type of business.

If they really wanted to, they could have layered each service into ads and non-ad subscriptions just like Spotify does.

If muddying their premium service is taboo, then there are alternative solutions.

I understand and agree with Hastings that delivering “customer pleasure” is the ultimate goal, but that doesn’t mean there can’t be an ad-based model as one of the options.

I believe this is a substantial letdown to the shareholder and the stock price would be closer to $500 if there was a realistic ad revenue option.

Even worse, Hasting’s argument for not delving into digital ads is flawed by saying, “We don’t collect anything. We’re really focused on just making our members happy.”

That is materially false.

Netflix already tracks loads of data and it doesn’t take a Ph.D. data analyst to ignore that when you are busy perusing the Netflix platform, Netflix’s are tracked non-stop.  

Netflix uses algorithms to track user’s behavior through tracking viewership data in order to make critical decisions about which of its original programs should be renewed and which should be booted.

It also looks at overall viewing trends to make decisions about which new programs to pursue.

It then also tracks user's own engagement with Netflix’s content in order to personalize the Netflix home screen to user’s preference.

Netflix is already “exploiting users” and they are doing shareholders a massive disservice by not maximizing revenue to the full amount they can.

And yes, I do agree Netflix is not as good as Facebook, Google, and Amazon at tracking users, but the roadmap is certainly out there for Netflix to indulge in digital ads.

It would take less than 18 months for Netflix to be running on full cylinders if they poached a few experts.

Aside from the lack of digital ads, Netflix finally is starting to acknowledge the new competition from two major streaming services, Disney+ and Apple+ — both of which have subsidized their launch with free promotions in order to gain viewership.

Then it gets worse with streaming service Quibi, WarnerMedia’s HBO Max and NBCU’s Peacock rolling out.

The latter features a multi-tiered business model, including a free service for pay-TV subscribers, an ad-free premium tier and one that’s ad-supported.

Other TV streaming services also rely on ads for revenue, including Hulu and CBS All Access. Meanwhile, a number of ad-supported services are also emerging, like Roku’s The Roku Channel, Amazon’s IMDb TV, TUBI, Viacom’s Pluto TV, and others.

Considering much of Netflix’s rise is fueled on debt, it’s bonkers they aren’t going after every little bit of revenue that is there for the taking.

Netflix could lose 4 million subscribers this year, and sooner or later, Hastings will run out of places to hide.

Slowing domestic subscriber growth and bad guidance don’t sound like a roaring growth tech stock to me.

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-01-24 04:02:422020-05-11 13:08:52The Netflix Earnings Shocker
Mad Hedge Fund Trader

See You in Two Weeks

Diary, Newsletter

By the time you read this, I will be winging my way over the Pacific Ocean on my way to Fiji, Guadalcanal, and the better part of Australia, where I will be involved in fundraisers for fire relief. I’ll be making stops along the way to visit with my existing subscribers.

The Golden State has already sent 200 firefighters to the Land Down Under to advise on fighting these enormous conflagrations and we suffered our first three fatalities today, C130 pilots, who I happen to know well as I am one myself.

I am also making a stopover at Guadalcanal in the Solomon Island to make a documentary film about the epic WWII battle there for the 78th anniversary. I’ll send you the link to the video when it is finished.

In the meantime, I will be posting my options training course over the next ten days. We have recently taken in a large number of new subscribers and they will need to be instructed on the basics. Some of you veterans may have also forgotten what’s important so you should probably give a read as well.

I’ll be back on February 8 after an endless series of 42 hours of flights.

Good Luck and Good Trading

John Thomas
CEO & Publisher
The Diary of a Mad Hedge Fund Trader

 

https://www.madhedgefundtrader.com/wp-content/uploads/2019/12/fiji-e1577465965379.png 253 450 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-01-24 04:02:142020-01-23 22:38:03See You in Two Weeks
Mad Hedge Fund Trader

January 24, 2020 - Quote of the Day

Tech Letter

“If the Starbucks secret is a smile when you get your latte... ours is that the Web site adapts to the individual's taste.” – Said Founder of Netflix Reed Hastings

https://www.madhedgefundtrader.com/wp-content/uploads/2020/01/hastings.png 408 322 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-01-24 04:00:252020-01-23 23:14:06January 24, 2020 - Quote of the Day
Mad Hedge Fund Trader

Trade Alert - (TRIP) January 23, 2020 - BUY

Tech Alert

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/Alert-e1457452190575.jpg 135 150 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-01-23 13:52:012020-01-23 13:52:01Trade Alert - (TRIP) January 23, 2020 - BUY
Mad Hedge Fund Trader

Trade Alert - (AAPL) January 23, 2020 - SELL-TAKE PROFITS

Trade Alert

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/Alert-e1457452190575.jpg 135 150 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-01-23 10:50:352020-01-23 10:54:01Trade Alert - (AAPL) January 23, 2020 - SELL-TAKE PROFITS
Mad Hedge Fund Trader

January 23, 2020 - MDT Pro Tips A.M.

MDT Alert

While the Diary of a Mad Hedge Fund Trader focuses on investment over a one week to a six-month time frame, Mad Day Trader, provided by Bill Davis, will exploit money-making opportunities over a brief ten minute to three-day window. It is ideally suited for day traders, but can also be used by long-term investors to improve market timing for entry and exit points. Read more

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-01-23 09:51:012020-01-23 09:51:01January 23, 2020 - MDT Pro Tips A.M.
Mad Hedge Fund Trader

January 23, 2020

Diary, Newsletter, Summary

Global Market Comments
January 23, 2020
Fiat Lux

Featured Trade:

(AN AFTERNOON WITH ANTHONY SCARAMUCCI OF SKYBRIDGE),
(BRK/A), (EEM)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-01-23 04:04:142020-01-22 17:24:26January 23, 2020
Mad Hedge Fund Trader

January 23, 2020

Biotech Letter

Mad Hedge Biotech & Healthcare Letter
January 23, 2020
Fiat Lux

Featured Trade:

(BIOGEN’S BIG ALZHEIMER’S BET),
(BIIB), (BMY), (PFE), (IONS), (MYL)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-01-23 04:02:402020-01-23 10:57:08January 23, 2020
Mad Hedge Fund Trader

An Afternoon with Anthony Scaramucci of Skybridge

Diary, Newsletter

I asked Anthony Scaramucci, CEO and founder of Skybridge Capital, why we should attend his upcoming SALT conference point-blank.

“It’s going to be exciting,” he said.

“How exciting?” I enquired.

“I’ve invited former White House chief of staff General John F. Kelley to be my keynote speaker.” General Kelley, an old friend from my Marine Corps days, fired Anthony after only eight days on the job as Donald Trump’s Press Secretary.

“That’s pretty exciting,” I responded. “Humble too.”

This was the answer that convinced me to attend the May 7-10 SkyBridge Alternative asset management conference (SALT) at the Las Vegas Bellagio Hotel. You all know the Bellagio. That is the casino that was robbed in the iconic movie Oceans 11.

That is not all Scaramucci had to offer about the upcoming event, known to his friends since his college days as “The Mooch”.

Among the other headline, speakers are former UN ambassador Nikki Haley, AOL Time Warner founder Steve Case, artificial intelligence guru Dr. Kai-fu Lee who I have written about earlier, and Carlyle Group co-founder David Rubenstein.

SALT will give seasoned investors to update themselves on the hundreds of alternative investment strategies now in play in the market, raise or allocate money, meet fascinating people, and just plain have fun. Some SkyBridge services accept client investments as little as $25,000. Their end of conference party is legendary.

SkyBridge is led by Co-Managing Partners Anthony Scaramucci and Raymond Nolte.  Ray serves as the Firm’s Chief Investment Officer and Chairman of the Portfolio Allocation and Manager Selection Committees.  Anthony focuses on strategic planning and marketing efforts.

While I had “The Mooch” on the phone, I managed to get him to give me his 30,000-foot view of the seminal events affecting markets today.

The proliferation of exchange-traded funds and algorithms will end in tears. There are now more listed ETFs than listed stocks, over 3,500.

The normalizing of interest rates is unsustainable, which have been artificially low for ten years now. One rise too many and it will crash the market. The next quarter-point rise could be the stick that breaks the camel’s back (an appropriate metaphor for a desert investment conference).

However, rising rates are good for hedge funds as they present more trading opportunities and openings for relative outperformance, or “alpha.”

There has been a wholesale retreat of investment capital from the markets, at least $300 billion in recent years. The end result will be much higher volatility when markets fall as we all saw in the Q4 meltdown until this structural weakness has been obscured by ultra-low interest rates. The good news is that banks are now so overcapitalized that they will not be at risk during the next financial crisis.

Ever the contrarian and iconoclast, Scaramucci currently has no positions in technology stocks. He believes the sector has run too far too fast after its meteoric 2 ½ year outperformance and is overdue for a rest. Earnings need to catch up with prices and multiples.

What is Anthony’s favorite must-buy stock today? Berkshire Hathaway (BRK/A), run by Oracle of Omaha Warren Buffet,  is almost a guarantee to outperform the market. Scaramucci has owned the shares in one form or another for over 25 years.

While emerging markets (EEM) are currently the flavor of the day, Anthony won’t touch them either. The accounting standards and lack of rule of law are way too lax for his own high investment standards.

SkyBridge is avoiding the 220 IPOs this year which could total $700 billion. Many of these are overhyped with unproven business models and inexperienced management. The $100 billion in cash they actually take out of the market won’t be enough to crash it.

SkyBridge Capital is a global alternative investment firm with $9.2 billion in assets under management or advisement (as of January 31, 2019). The firm offers hedge fund investing solutions that address a wide range of market participants from individual investors to large institutions.

SkyBridge takes a high-conviction approach to alpha generation expressed through a thematic and opportunistic investment style. The firm manages multi-strategy funds of hedge funds and customized separate account portfolios, and provides hedge fund advisory services. SkyBridge also produces a large annual conference in the U.S. and Asia known as the SkyBridge Alternatives Conference (SALT).
 
Finally, I asked Anthony, if he were king of the world what change would he make to the US today? “If I could wave a magic wand, I would reduce partisanship,” he replied. “It prevents us from being our best.” Will he ever go back into politics again? “Never say never,” he shot back wistfully.

With that, I promised to give him a hug the next time I see him in Vegas which I have been visiting myself since 1955 during the rat pack days.
 
To learn more about SkyBridge, please visit their website here.

To obtain details about the upcoming May 7-10 SALT conference at the Bellagio Hotel in Las Vegas, please click here. Better get a move on. Their discount pricing for the event ends on March 15. Institutional Investors are invited free of charge.

 

 

 

https://www.madhedgefundtrader.com/wp-content/uploads/2018/11/John-Thomas-with-lady-in-red.png 495 541 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-01-23 04:02:212020-05-11 14:14:33An Afternoon with Anthony Scaramucci of Skybridge
Mad Hedge Fund Trader

Biogen’s Big Alzheimer’s Bet

Biotech Letter

Biotech giant Biogen (BIIB) failed to impress in 2019. Surprisingly, the company is sticking to its strategy this 2020.

Despite the majority of biotech companies posting market-beating gains last year, Biogen’s shares suffered a 1.4% loss to their value. Taking a look at its performance, there are three obvious reasons why Biogen stock lost ground in 2019.

For one, its revenue generation, particularly for the multiple sclerosis portfolio, flatlined last year. Another reason is the company’s move not to acquire another company the way Bristol-Myers Squibb (BMY) took over Celgene.

Biogen’s decision to not make any major acquisition in 2019 was deemed as an inability to achieve significant business development milestones, thereby failing to positively influence the company’s near-term outlook.  

The third reason is Biogen’s decision to halt trials for its widely anticipated Alzheimer’s drug candidate, Aducanumab, in March 2019.

With so much invested in the development of this product, the investing community expected Biogen to completely drop the project altogether.

However, it seems that Biogen has found a way to resolve the issues it initially encountered in the Aducanumab study.

In October 2019, the company announced its plan to resurrect all its Aducanumab-related efforts. To show its commitment to the plan, Biogen kicked off 2020 with a massive purchase from Pfizer (PFE).

Since Biogen aims to apply for regulatory approval by early 2020, the company has been aggressively pursuing avenues to ensure that its Alzheimer’s drug candidate will get the green light as soon as possible.

One of its efforts is its $700 million deal to buy Pfizer’s castoff drug, PF-05251749.

The Pfizer drug was created to treat Irregular Sleep-Wake Rhythm Disorder suffered by Alzheimer’s and Parkinson’s disease patients. This condition, also known as Sundowning, affects 20% of those afflicted by these neurological diseases.

According to the terms of the deal, Biogen will shell out $75 million upfront to gain the rights to the Pfizer drug.

The company will also pay an additional $635 million in the form of milestone payments. Pfizer will receive tiered royalties as well.

On top of this $700 million deal with Pfizer, Biogen also added another $45 million to fund its Alzheimer’s research with Ionis Pharmaceuticals (IONS). Apart from these, the two companies have been working on ION859, which is a possible treatment for Parkinson’s disease.

As if all of these are not enough to show Biogen’s dedication to finding the cure for Alzheimer’s disease, the company has a similar drug in its pipeline: BAN2401. This new drug, which uses a similar approach to Aducanumab, is actually already in its late-stage testing phase.

However, Biogen’s deal with Pfizer is not the first of its kind.

Prior to this, the company paid a whopping $300 million upfront to Bristol-Myers Squibb to own the rights to neurological drug Gosuranemab. Unfortunately, that study failed to deliver the desired results.

Even though Biogen has yet to actually file for regulatory approval for Aducanumab, the company is already preparing for the treatment’s launch this year. This is a rather confident move especially in light of the niggling doubts on the drug’s approval.

Apart from working on Aducanumab, Biogen has been testing for a higher dosage for spinal muscular atrophy medication Spinranza. This is done as a precautionary measure against Novartis’ (NVS) blockbuster gene therapy Zolgensma.

Its exclusive rights on Tecfidera, which has been challenged by Mylan (MYL), is also anticipated to hold until 2028. This means Biogen can still expect to reign supreme in this niche, hanging on to its blockbuster drug that raked in $4.3 billion in 2018 alone and $2.15 billion in the first half of 2019.

In addition to Alzheimer’s and Parkinson’s disease, Biogen is active in searching for treatments for Lou Gehrig’s disease along with stroke and choroideremia as well.

Biogen has also set in motion its plan to venture into rare eye diseases via its $800 million acquisition of Nighstar Therapeutics back in June 2019.

Notably, though, Biogen has been steering away from any major acquisition in 2020.

This strategy could be a stroke of genius if the company’s bet on Aducanumab pays off.

 

https://www.madhedgefundtrader.com/wp-content/uploads/2020/01/biogen.png 312 899 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-01-23 04:00:362020-01-23 10:57:00Biogen’s Big Alzheimer’s Bet
Page 1009 of 2206«‹10071008100910101011›»

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2026. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
Scroll to top